Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099486 · ClinicalTrials.gov registry record · Phase 2
Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03099486: Clinical Trial Phase 2 study, sponsored by Fox Chase Cancer Center.
NCT03099486 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03099486, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent combination chemotherapy and progression on regorafenib monotherapy.
Primary Outcome
PFS at 2 months in mCRC patients who progress on regorafenib monotherapy and are treated with regorafenib and 5-FU/LV combination therapy.
Interventions
- DRUG Leucovorin
- DRUG Regorafenib
- DRUG 5-FU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-10-06 |
| Est. Completion | 2020-06-02 |
| Phase | Phase 2 |
Why NCT03099486 stopped before completion
NCT03099486 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Leucovorin is the first listed.
NCT03099486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03099486 about?
NCT03099486 is a clinical study titled "Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC". This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent com...
What is the current status of trial NCT03099486?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-10-06. Estimated completion is 2020-06-02.
What interventions are being tested in trial NCT03099486?
The interventions under investigation include: Leucovorin (DRUG), Regorafenib (DRUG), 5-FU (DRUG).
Who is sponsoring clinical trial NCT03099486?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03099486's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI